URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Alejandro Galindo net worth and biography

Alejandro Galindo Biography and Net Worth

Insider of MannKind

Alejandro Galindo is Chief Commercial Officer of MannKind Corp. and Vice President at Goodman Factors, Inc.

Mr. Galindo previously occupied the position of VP & President-Intensive Insulin Management at Medtronic Plc.

He received an MBA and a graduate degree from Indiana University and an undergraduate degree from Instituto Tecnológico y de Estudios Superiores de Monterrey.

What is Alejandro Galindo's net worth?: The estimated net worth of Alejandro Galindo is at least $5.32 million as of August 22nd, 2022. Mr. Galindo owns 777,075 shares of MannKind stock worth more than $5,322,964 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Galindo may own. Learn More about Alejandro Galindo's net worth.
How do I contact Alejandro Galindo?: The corporate mailing address for Mr. Galindo and other MannKind executives is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. MannKind can also be reached via phone at (818) 661-5000 and via email at [email protected]. Learn More on Alejandro Galindo's contact information.
Has Alejandro Galindo been buying or selling shares of MannKind?: Alejandro Galindo has not been actively trading shares of MannKind over the course of the past ninety days. Most recently, Alejandro Galindo sold 4,615 shares of the business's stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $3.85, for a transaction totalling $17,767.75. Following the completion of the sale, the executive vice president now directly owns 777,075 shares of the company's stock, valued at $2,991,738.75. Learn More on Alejandro Galindo's trading history.
Who are MannKind's active insiders?: MannKind's insider roster includes Steven Binder (CFO), Michael Castagna (CEO), Alejandro Galindo (Insider), David Thomson (EVP), and Stuart Tross (Insider). Learn More on MannKind's active insiders.
Are insiders buying or selling shares of MannKind?: In the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 415,227 shares worth more than $2,696,774.66. The most recent insider tranaction occured on November, 22nd when Director Steven B Binder sold 67,536 shares worth more than $465,323.04. Insiders at MannKind own 3.0% of the company. Learn More about insider trades at MannKind.
Information on this page was last updated on 11/22/2024.

Alejandro Galindo Insider Trading History at MannKind

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/22/2022	Sell	4,615	$3.85	$17,767.75	777,075
7/31/2022	Buy	5,000	$2.93	$14,650.00	781,690
2/28/2022	Buy	36,900	$2.71	$99,999.00
1/31/2022	Buy	2,334	$3.17	$7,398.78
11/14/2020	Buy	34,602	$2.89	$99,999.78	398,602

Alejandro Galindo Buying and Selling Activity at MannKind

MannKind Company Overview

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Today's Range

Now: $6.85

$6.30

$7.07

50 Day Range

MA: $6.75

$5.93

$7.44

2 Week Range

Now: $6.85

$3.17

$7.63

Volume

7,214,138 shs

Average Volume

2,616,986 shs

Market Capitalization

$1.89 billion

P/E Ratio

97.86

Dividend Yield

N/A

Beta

1.28

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.